Haleon (HAM:H6D) Other Stockholders Equity: €-12,985 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:H6D Haleon PLC HAM:H6D
76 GF Score
Price €8.75
GF Value €8.53
! 5 Warning Signs
View Full Analysis

What is Haleon Other Stockholders Equity?

Haleon HAM:H6D 76 Other Stockholders Equity is €-12,985 Mil as of Dec. 2025. GuruFocus rates HAM:H6D with a GF Score™ of 76/100 and a GF Value™ of €8.53. The stock has 5 warning signs investors should review.

Haleon's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €-12,985 Mil.

Haleon's quarterly Other Stockholders Equity declined from Dec. 2024 (€-13,380 Mil) to Jun. 2025 (€-13,430 Mil) but then increased from Jun. 2025 (€-13,430 Mil) to Dec. 2025 (€-12,985 Mil).

Haleon's annual Other Stockholders Equity declined from Dec. 2023 (€-12,722 Mil) to Dec. 2024 (€-13,380 Mil) but then increased from Dec. 2024 (€-13,380 Mil) to Dec. 2025 (€-12,985 Mil).

Haleon Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Haleon's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleon Other Stockholders Equity Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial -13,162.02 -12,062.73 -12,721.92 -13,379.66 -12,984.92

Haleon Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,721.92 -13,021.37 -13,379.66 -13,429.68 -12,984.92
HAM:H6D
76GF Score
Haleon PLC HAM:H6D
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleon Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-12,985 Mil mean?
Haleon (HAM:H6D) has a Other Stockholders Equity of €-12,985 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Haleon and its competitors.
Is Haleon's Other Stockholders Equity too high?
Haleon's current Other Stockholders Equity is €-12,985 Mil. Overall, Haleon has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's Other Stockholders Equity compare to ZTS and UTHR?
Haleon's Other Stockholders Equity of €-12,985 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Haleon and its competitors. Haleon's current Other Stockholders Equity is €-12,985 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (HAM:H6D) has a current Other Stockholders Equity of €-12,985 Mil. The stock's GF Value™ is €8.53, compared to a current price of €8.75 — trading 2.6% above its estimated fair value. The current Other Stockholders Equity is €-12,985 Mil. Haleon's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Haleon (HAM:H6D), the current Other Stockholders Equity is €-12,985 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleon (HAM:H6D) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be overvalued. The current stock price of €8.75 is trading 2.6% above its estimated GF Value™ of €8.53.

Key valuation signals for HAM:H6D:

  • Other Stockholders Equity: €-12,985 Mil
  • GF Value™: €8.53 vs. price of €8.75 (2.6% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the HAM:H6D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
76GF Score

Get the complete analysis for HAM:H6D

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.75
Price
€8.53
GF Value